Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Marburg virus VP24 protein is a minor matrix protein integral to the viral life cycle. It is involved in the assembly of the viral nucleocapsid and in budding of new virus particles from the host cell. VP24 colocalizes with nucleoprotein inclusions in infected cells and displays membrane-binding properties but cannot form virus-like particles (VLPs) independently—it is incorporated into VLPs by association with the major matrix protein VP40. Inhibition or silencing of VP24 reduces release of Marburg virions. Structurally, Marburg VP24 has a single-domain alpha/beta fold with a unique projecting β-shelf, distinct from ebolavirus VP24, and does not possess the strong immunosuppressive function of its Ebola counterpart[1][3][4][8].
Experimental antivirals could act by inhibiting VP24’s interaction with other viral proteins or with membranes, thereby impairing virion assembly and release
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Marburg virus VP24 protein (VP24).